Electromed (ELMD) Investor presentation summary

Company overview and market position

• Focuses on airway management medical devices, with headquarters in Minnesota and a market cap of $204M as of March 2025.

• Annual revenue reached $61.5M with 181 employees and manufacturing based in Minnesota.

• Operates in the large, expanding airway clearance market, primarily targeting bronchiectasis and related conditions.

Product innovation and clinical impact

• SmartVest Airway Clearance System uses HFCWO technology, supported by clinical outcomes and strong reimbursement.

• Enhanced patient experience with a lightweight, portable device and intuitive interface.

• SmartNotes™ provides physicians with detailed patient progress and therapy utilization data.

• Clinical studies show significant reductions in hospitalizations, antibiotic use, and emergency visits for users.

Market opportunity and penetration

• U.S. bronchiectasis market is underpenetrated, with only ~15% HFCWO adoption among diagnosed patients.

• Diagnosed bronchiectasis population is growing at ~12% annually, with an estimated 4.1 million undiagnosed cases.

• Homecare represents 94% of net revenue, with 52% from Medicare and 46% from commercial/other payers.